Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1993-7-30
|
| pubmed:abstractText |
A truncated herpes simplex virus (HSV) type 1 glycoprotein D (t-gD) gene was fused to the human interleukin-2 (IL-2) gene (t-gD-IL-2 gene) and introduced into mouse myeloma Sp2/0 cells. The gene product, t-gD-IL-2, secreted from the cells was immunoprecipitated with five monoclonal antibodies specific for native gD. Purified t-gD-IL-2 supported the growth of IL-2-dependent cells, with a specific activity almost comparable to that of recombinant human IL-2. Mice immunized with t-gD-IL-2 in an adjuvant-free form showed superior anti-HSV antibody responses, and were completely protected against HSV challenge, whereas immunization with t-gD adsorbed onto aluminum hydroxide (alum) partially failed to prevent the virus infection. The high immunogenicity of t-gD-IL-2 was due to the biological activity of the fused IL-2 rather than to a hapten-carrier effect of the IL-2 moiety, because mice primed with t-gD-IL-2 showed delayed-type hypersensitivity against stimulation with gD, but not against that with IL-2 antigen, and because a booster immunization with t-gD-IL-2 extensively augmented the response of anti-gD antibody, but not that of the anti-human IL-2 antibody. The serological half-life of IL-2 activity in mice injected with t-gD-IL-2 was prolonged to about four times that of rIL-2. However, when t-gD-IL-2 was co-administered with human albumin (HSA), the mouse anti-HSA antibody response was slightly enhanced.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Haptens,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Envelope Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/glycoprotein D, Human herpesvirus 1
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0264-410X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
629-36
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8391739-Adjuvants, Immunologic,
pubmed-meshheading:8391739-Animals,
pubmed-meshheading:8391739-Antibodies, Viral,
pubmed-meshheading:8391739-Base Sequence,
pubmed-meshheading:8391739-Cell Line,
pubmed-meshheading:8391739-Female,
pubmed-meshheading:8391739-Half-Life,
pubmed-meshheading:8391739-Haptens,
pubmed-meshheading:8391739-Herpes Simplex,
pubmed-meshheading:8391739-Interleukin-2,
pubmed-meshheading:8391739-Mice,
pubmed-meshheading:8391739-Mice, Inbred BALB C,
pubmed-meshheading:8391739-Molecular Sequence Data,
pubmed-meshheading:8391739-Recombinant Fusion Proteins,
pubmed-meshheading:8391739-Simplexvirus,
pubmed-meshheading:8391739-Vaccination,
pubmed-meshheading:8391739-Vaccines, Synthetic,
pubmed-meshheading:8391739-Vero Cells,
pubmed-meshheading:8391739-Viral Envelope Proteins,
pubmed-meshheading:8391739-Viral Vaccines
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
|
| pubmed:affiliation |
Biology Research Laboratories, Takeda Chemical Industries Ltd, Osaka, Japan.
|
| pubmed:publicationType |
Journal Article
|